Acadia Pharmaceuticals
ACAD
ACAD
232 hedge funds and large institutions have $2.97B invested in Acadia Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 76 increasing their positions, 70 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
9% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 70
0.8% more ownership
Funds ownership: 96.2% → 97% (+0.8%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Holders
232
Holding in Top 10
5
Calls
$10.9M
Puts
$4.48M
Top Buyers
| 1 | +$86M | |
| 2 | +$23.1M | |
| 3 | +$22M | |
| 4 |
D.E. Shaw & Co
New York
|
+$12.8M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$10.9M |
Top Sellers
| 1 | -$40.5M | |
| 2 | -$28M | |
| 3 | -$23.8M | |
| 4 |
Man Group
London,
United Kingdom
|
-$15.2M |
| 5 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$11.2M |